BostonGene and the Medical College of Wisconsin Announce the Publication and Journal Cover Feature in Gastroenterology Highlighting Transcriptomic-Based Tumor Microenvironment Classification for Precision Medicine in Pancreatic Cancer
06 Mayo 2024 - 7:50AM
Business Wire
Study reveals four distinct tumor
microenvironment subtypes in pancreatic ductal adenocarcinoma,
guiding personalized treatment decisions
BostonGene, a leading provider of AI-driven molecular and immune
profiling solutions, and the Medical College of Wisconsin, today
announced the manuscript “Transcriptomic-Based Microenvironment
Classification Reveals Precision Medicine Strategies for PDAC'' has
published online and in print in Gastroenterology, the premier
journal in the field of gastrointestinal disease. BostonGene’s
artwork was also chosen for the cover of the May publication. The
journal highlights original research, reviews and expert insights
in adult and pediatric gastroenterology and hepatology, covering
clinical, translational and basic aspects of the digestive system,
liver, pancreas and nutrition. The study identified four distinct
tumor microenvironment (TME) subtypes, unveiling a promising path
forward in the fight against PDAC and underscoring the importance
of considering TME features in personalized therapeutic
strategies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240506047340/en/
Pancreatic ductal adenocarcinoma (PDAC) has long been notorious
for its aggressive nature and genetic complexity, making it
difficult for doctors to predict how patients will respond to
treatment and for scientists to develop effective predictive
biomarkers and targeted therapies. To address these unmet needs,
Ben George, MD, at the Medical College of Wisconsin (MCW) in
collaboration with BostonGene, led a study utilizing a
transcriptomic profiling platform to classify the TME of PDAC based
on functional gene expression signatures. This innovative approach
analyzed data from publicly available PDAC datasets and was further
validated in a clinically annotated, independent cohort of PDAC
patients from the LaBahn Pancreatic Cancer Program, part of the MCW
Cancer Center.
“For a long while, the scientific community believed that
pancreatic cancer was not responsive to immunotherapy, which uses a
person’s own immune system to fight cancer. We’ve since made new
discoveries that show that pancreatic cancer that spreads to the
lungs is biologically distinct, prognostically favorable, and
potentially responsive to immunotherapy compared to those that
spread to the liver,” said Ben George, MD, William F. Stapp Endowed
Chair; Professor of Medicine and Medical Director, Cancer Clinical
Trials Program at the Medical College of Wisconsin. “Together with
BostonGene, we hope to further characterize the biologically
distinct PDAC subtypes and investigate how different treatments can
modify the TME of pancreatic cancers. Our goal is to design
prospective clinical trials, which will be made available through
the MCW Cancer Center, to test various immunomodulatory strategies
based on these four subtypes.”
As part of the collaboration, BostonGene utilized an artificial
intelligence (AI)-driven algorithm to reconstruct the
transcriptomic data and identified four distinct TME subtypes:
immune-enriched (IE), immune-enriched with fibrosis (IE/F),
fibrotic (F) and immune-depleted (D). Importantly, patients with
immune-enriched subtypes, IE and IE/F, demonstrated a more
favorable prognosis and showed potential responsiveness to
immunotherapy than those classified as F and D.
"We're excited to unveil our latest research, which sheds light
on the intricate tumor microenvironment of PDAC," said Ben George.
"These results pave the way for transcriptomic-based
immunotherapeutic strategies in PDAC, bringing us closer to
personalized treatment approaches for this challenging
disease."
"Our findings not only define a subgroup of PDAC patients who
may benefit from immunotherapeutic interventions but also sets the
stage for prospective clinical trials to validate the predictive
utility of these transcriptomic TME PDAC subtypes,” said Nathan
Fowler, MD, Chief Medical Officer at BostonGene.
About BostonGene Corporation
BostonGene has a mission to provide transformative,
AI-integrated molecular analytics and biomarker discovery for
precision matching of therapies to improve the lives of patients
living with cancer and other immune-related diseases. BostonGene’s
concierge-service model provides customized client solutions using
a multi-omic approach prioritized for real-world impact to optimize
standard-of-care therapies, accelerate research and provide
cost-effective, measurable data-driven results. BostonGene’s tests
reveal key drivers of each patient’s unique disease profile,
including an in-depth profile of the immune microenvironment,
actionable mutations, biomarkers of response to diverse therapies,
and recommended therapies. Through these comprehensive analyses,
BostonGene’s tests generate a personalized roadmap for therapeutic
decision-making for each patient. For more information, visit
BostonGene at http://www.BostonGene.com.
About the Medical College of Wisconsin
With a history dating back to 1893, The Medical College of
Wisconsin is dedicated to leadership and excellence in education,
patient care, research and community engagement. More than 1,400
students are enrolled in MCW’s medical school and graduate school
programs in Milwaukee, Green Bay and Central Wisconsin. MCW’s
School of Pharmacy opened in 2017. A major national research
center, MCW is the largest research institution in the Milwaukee
metro area and second largest in Wisconsin. In the last 10 years,
faculty received more than $1.5 billion in external support for
research, teaching, training and related purposes. This total
includes highly competitive research and training awards from the
National Institutes of Health (NIH). Annually, MCW faculty direct
or collaborate on more than 3,100 research studies, including
clinical trials. Additionally, more than 1,600 physicians provide
care in virtually every specialty of medicine for more than 2.8
million patients annually.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506047340/en/
Media: BostonGene Erin O’Reilly +1-617-283-2285
Erin.Oreilly@BostonGene.com